Cwm LLC Sells 340 Shares of GeneDx Holdings Corp. $WGS

Cwm LLC lessened its holdings in shares of GeneDx Holdings Corp. (NASDAQ:WGS) by 13.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,150 shares of the company’s stock after selling 340 shares during the quarter. Cwm LLC’s holdings in GeneDx were worth $198,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Aberdeen Group plc bought a new stake in GeneDx during the 2nd quarter valued at approximately $12,622,000. Slow Capital Inc. bought a new stake in GeneDx during the 2nd quarter valued at approximately $3,614,000. Chung Wu Investment Group LLC grew its holdings in GeneDx by 8.2% during the 2nd quarter. Chung Wu Investment Group LLC now owns 3,300 shares of the company’s stock valued at $305,000 after buying an additional 250 shares in the last quarter. Perigon Wealth Management LLC purchased a new position in GeneDx during the 2nd quarter valued at approximately $479,000. Finally, SJS Investment Consulting Inc. grew its holdings in GeneDx by 19.9% during the 2nd quarter. SJS Investment Consulting Inc. now owns 4,280 shares of the company’s stock valued at $395,000 after buying an additional 709 shares in the last quarter. Institutional investors own 61.72% of the company’s stock.

GeneDx Price Performance

Shares of GeneDx stock opened at $137.47 on Wednesday. The stock has a market cap of $3.95 billion, a price-to-earnings ratio of 2,749.40 and a beta of 1.98. The company has a debt-to-equity ratio of 0.19, a quick ratio of 2.70 and a current ratio of 2.87. The stock has a 50 day moving average price of $123.66 and a 200-day moving average price of $98.28. GeneDx Holdings Corp. has a one year low of $55.17 and a one year high of $146.00.

GeneDx (NASDAQ:WGS) last posted its quarterly earnings data on Tuesday, July 29th. The company reported $0.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.10 by $0.40. GeneDx had a return on equity of 16.51% and a net margin of 0.39%.The company had revenue of $102.69 million during the quarter, compared to analysts’ expectations of $86.00 million. Equities analysts expect that GeneDx Holdings Corp. will post 0.97 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Piper Sandler raised their price target on GeneDx from $120.00 to $140.00 and gave the company an “overweight” rating in a report on Thursday, September 11th. Wells Fargo & Company raised their price target on GeneDx from $78.00 to $95.00 and gave the company an “equal weight” rating in a report on Wednesday, July 30th. Canaccord Genuity Group set a $155.00 price target on GeneDx and gave the company a “buy” rating in a report on Monday, October 20th. Wall Street Zen upgraded GeneDx from a “hold” rating to a “buy” rating in a report on Saturday, August 2nd. Finally, Weiss Ratings restated a “sell (d)” rating on shares of GeneDx in a report on Wednesday, October 8th. Eight investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $112.80.

Insider Activity at GeneDx

In other GeneDx news, CEO Katherine Stueland sold 10,501 shares of GeneDx stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $121.47, for a total transaction of $1,275,556.47. Following the completion of the sale, the chief executive officer directly owned 14,578 shares of the company’s stock, valued at $1,770,789.66. The trade was a 41.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Kevin Feeley sold 3,728 shares of GeneDx stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $121.47, for a total value of $452,840.16. Following the sale, the chief financial officer directly owned 8,755 shares of the company’s stock, valued at approximately $1,063,469.85. This trade represents a 29.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 553,829 shares of company stock valued at $67,221,616. 29.60% of the stock is owned by insiders.

GeneDx Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.